Targeting Latexin for radiation mitigation.

针对 Latexin 进行辐射缓解。

基本信息

批准号：
9925204
负责人：
SOMASUNDAR PRASAD GABBITA
金额：
$ 28.43万
依托单位：
P2D, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-06 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9925204
关键词：
Accidents Acute Affect Animals Attention Binding Binding Proteins Biological Assay Biology Blood Blood Cells Bone Marrow Carboxypeptidase Cell Count Cell physiology Cessation of life Chemicals Dose Emergency Situation FDA approved Goals Gold Grant Granulocyte Colony-Stimulating Factor Hematologic Neoplasms Hematopoiesis Hematopoietic Hematopoietic stem cells Hemorrhage Hour In Vitro Infection Injury Ionizing radiation Lead Life Medical Metabolic Mus Natural regeneration Nuclear Accidents Nuclear Radiology PC3.1 antigen Pancytopenia Pathology Pathway interactions Pharmaceutical Preparations Pharmacology Pharmacotherapy Proteins Radiation Radiation Accidents Radiation Injuries Radiation Toxicity Radiation exposure Radiation induced damage Radio Reagent Regimen Risk Role Safety System Testing Therapeutic Tissues Toxic effect Transplantation Up-Regulation Whole-Body Irradiation Work analog base design effective therapy efficacy study experimental study functional disability genetic regulatory protein improved in vivo inhibitor/antagonist irradiation knock-down mass casualty medical countermeasure novel novel therapeutic intervention novel therapeutics pyridine radiation mitigation radiation response radiation-induced injury radiological attack screening self-renewal tissue injury

项目摘要

The purpose of this grant is to develop novel therapeutic approaches for radiological/nuclear medical countermeasures. Very few medical products have been shown to counter the acute and long-term injuries that can result from a nuclear or radiological accident or attack. Medical products and regimens that mitigate and/or treat radiation injury post-exposure (i.e., administration of first dose to start at least 24 hours after radiation exposure), with emphasis on ease of administration in a mass casualty and emergency scenario; safety; and long shelf-life are still to be developed and are thus of high priority. Therapeutic administration of a drug that inhibits the activity of the protein latexin in hematopoietic stem cells (HSCs) resulted in mitigation of HSC function. These findings suggest that pharmacologic augmentation of the activity of such a drug, in combination with additional mitigators currently developed, might offer a rational approach to the mitigation of tissue injury and lethality caused by ionizing radiation that especially affects hematopoiesis.

这笔赠款的目的是开发新颖的治疗方法放射/核医学对策。很少有医疗产品证明可以应对可能由核或长期的急性和长期伤害放射学事故或攻击。减轻和/或治疗的医疗产品和方案暴露后辐射损伤（即，初次剂量至少开始24小时辐射暴露后），重点是在大规模伤亡中易于给药和紧急情况；安全;和长长的保质期仍在开发中，因此优先级。治疗给药的药物抑制了造血干细胞（HSC）中的蛋白质乳胶素导致HSC功能的减轻。这些发现表明，这种药物活性的药理增强，结合当前开发的其他缓解剂，可能会提供合理的通过电离辐射引起的组织损伤和致死性的方法特别影响造血。